ClinicalTrials.gg
CompletedNCT01140607Updated Jul 21, 2015

Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment

A Phase 1 interventional study of Cabazitaxel (XRP6258) in Neoplasm Malignant, sponsored by Sanofi. Completed at 14 sites in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2015-07-21.

Sponsored by Sanofi · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
56
Allocation
Non-randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

Primary Objectives:

  • To determine the maximum tolerated dose (MTD) and safety of Cabazitaxel when administered to advanced solid tumor patients with varying degrees of hepatic impairment
  • To determine the pharmacokinetics (PKs) of Cabazitaxel in patients with varying degrees of hepatic impairment
  • To correlate PK variables with pharmacodynamic (PD) safety parameters in order to guide prescribers with regard to dosing in this patient population
  • To assess the effect of cabazitaxel at recommended dose of 25mg/m\^2 on CYP3A enzyme activity using midazolam as probe in an additional cohort of cancer patients with normal hepatic function.
Read the detailed description

The study consists of:

  • a screening phase (maximum length of 21-day).
  • a treatment phase with 21-day study treatment cycles. Cycle lengths may be extended up to maximum of 12 additional days in case of unresolved toxicity.

Patients continue to receive treatment until they experience, unacceptable toxicities/AEs, disease progression ,withdraw their consent, or the investigator decides to discontinue the patient, or study cut-off, whichever comes first.

  • a 30-day follow-up visit after the last dose of study medication.

The cut off date is when the last patient treated has completed cycle 1 and the subsequent 30 days follow-up.

Patients may continue to be treated as long as they are benefiting from study treatment and have not met study withdrawal criteria.

02

Conditions studied

  • Neoplasm Malignant

Browse trials for

03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,325 are open to participants now.

This study's enrollment of 56 is close to the median of 60 across 7,706 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with a diagnosis of advanced, measurable or non-measurable, non-hematological cancer who have varying degrees of hepatic impairment. The cancer must be one that is either to standard therapy or for which no standard therapy exists.

Exclusion criteria

Exclusion criteria:

  • (ECOG) performance status (PS) >2
  • \<3 months
  • Need for a major surgical procedure or radiation therapy during the study
  • Evidence of another active
  • Prior chemotherapy, other drug, biological therapy, targeted non-cytotoxic therapy and radiotherapy within 3 weeks prior to registration
  • Patients with known history of Gilbert's syndrome
  • Prior treatment with Cabazitaxel and a history of severe (Grade ≥3) to taxanes, polysorbate-80, or to compounds with similar chemical structures
  • Prior history of bone marrow transplant
  • Any treatment known to induce CYP isoenzymes or to inhibit activities within 2 weeks before or during the test period of the pharmacokinetic sampling. Moderate inhibitors within one week prior and during the pharmacokinetic sampling.
  • Any to midazolam, according to the applicable labeling.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    Cohort 1: normal hepatic function: cabazitaxel

    cabazitaxel 25mg/m\^2 IV infusion of Cabazitaxel is given over 1 hour on Day 1 of each cycle (every 3 weeks).

    Drug: Cabazitaxel (XRP6258)

  • Experimental
    Cohort 2: mild hepatic impairment : cabazitaxel

    cabazitaxel 20mg/m\^2 IV infusion of Cabazitaxel is given over 1 hour on Day 1 of each cycle (every 3 weeks).

    Drug: Cabazitaxel (XRP6258)

  • Experimental
    Cohort 3: moderate hepatic impairment: cabazitaxel

    cabazitaxel 10mg/m\^2 IV infusion of Cabazitaxel is given over 1 hour on Day 1 of each cycle (every 3 weeks).

    Drug: Cabazitaxel (XRP6258)

  • Experimental
    Cohort 4: severe hepatic impairment: cabazitaxel

    cabazitaxel 5 mg/m\^2 or 10mg/m\^2 IV infusion of Cabazitaxel is given over 1 hour on Day 1 of each cycle (every 3 weeks).

    Drug: Cabazitaxel (XRP6258)

  • Experimental
    Cohort 5: normal hepatic function: cabazitaxel and midazolam

    cabazitaxel 25mg/m\^2 IV infusion of Cabazitaxel is given over 1 hour on Day 1 of each cycle (every 3 weeks). Midazolam is given orally in single dosing on day -1 and day 1 (crossover)

    Drug: Cabazitaxel (XRP6258)

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of Dose Limiting Toxicities (DLT)

    A clinical adverse event or a laboratory abnormality is defined as DLT when it is drug-related as assessed by the investigator and agreed upon by the study committee.

    Time frame: cycle 1 (3 weeks)

Secondary outcomes

  1. Safety investigations (physical examination, vital signs and laboratory tests)

    Physical examination includes Eastern Cooperative Oncology Group (ECOG) performance status and signs and symptoms. Vital signs includes weight, temperature, blood pressure and heart rate. Laboratory tests includes hematology, coagulation, biochemistry and urinalysis. Laboratory abnormalities are graded according to the NCI CTCAE v.4.0

    Time frame: up to 30 days after the last dosing

  2. Pharmacokinetic profile of Cabazitaxel (AUC, Cmax, t1/2, CL, and Vss) from plasma concentration

    Time frame: cycle 1 (3 weeks)

  3. Cabazitaxel effect on CYP3A enzyme activity

    Time frame: single dosing on day -1 and day 1

07

Study locations

14 sites
  • Investigational Site Number 840014
    La Jolla, California 92093, United States
  • Investigational Site Number 840013
    Loma Linda, California 92354, United States
  • Investigational Site Number 840020
    Washington, District of Columbia 20037, United States
  • Investigational Site Number 840016
    Jacksonville, Florida 32207, United States
  • Investigational Site Number 840002
    Tampa, Florida 33612, United States
  • Investigational Site Number 840017
    Decatur, Illinois 62526, United States
  • Investigational Site Number 840003
    Metairie, Louisiana 70006, United States
  • Investigational Site Number 840019
    Baltimore, Maryland 21201, United States
  • Investigational Site Number 840012
    Boston, Massachusetts 02115, United States
  • Investigational Site Number 840001
    St Louis, Missouri 63110, United States
  • Investigational Site Number 840021
    Canton, Ohio 44718, United States
  • Investigational Site Number 840007
    Cincinnati, Ohio 45267-0542, United States
  • Investigational Site Number 840010
    Bethlehem, Pennsylvania 18015, United States
  • Investigational Site Number 840006
    San Antonio, Texas 78229, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2010, a primary completion of Jul 2014 and a completion of Jul 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2010
First posted
Jun 9, 2010
Start
May 2010
Primary completionActual
Jul 2014
CompletionActual
Jul 2014
Last update
Jul 21, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01140607
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Jun 9, 2010
Start date
May 2010
Primary completion
Jul 2014
Completion
Jul 2014
Last update
Jul 21, 2015

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cabazitaxel

Start the discussion